Join the Immunogenicity of Biologics, Biopharmaceuticals & ATMPs Live Training Course on 23–24 September 2026 (13:00–18:00 CEST), an advanced online training designed for professionals involved in biologics, biosimilars, vaccines, monoclonal antibodies, and advanced therapy medicinal products (ATMPs). This intensive two-day course provides practical insights into immunogenicity risk assessment, anti-drug antibody (ADA) characterization, bioanalytical methods, assay development, quality control, and global regulatory requirements.
Participants will learn how to identify, assess, monitor, and mitigate immunogenicity risks throughout preclinical and clinical development. Expert trainers Dr. Thorsten Meyer (Granzer Regulatory Consulting, Germany), Marion Prior (VelaLabs, Austria), and DI Markus Roucka (former VelaLabs/Tentamus, Austria) will share real-world case studies, regulatory expectations, and practical strategies for minimizing immunogenicity challenges in biologics and ATMP development.